LONN Share Price Performance
CHF 548.00
-17.20 (-3.04%)
19.1% undervalued intrinsic discount
CHF 677.61
Fair Value
Price CHF 548.00
AnalystConsensusTarget CHF 677.61
Fair ValueCHF 677.61
Share Pricen/a
Narrative Update • Jul 24
Lonza Group AG Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 44 Fair Values set on narratives written by author
LONN Community Narratives
AN
Fair Value
·Fair Value CHF 677.61 19.1% undervalued intrinsic discount
Vacaville And Visp Facilities Will Secure Future Biologics Demand
0users have liked this narrative
0users have commented on this narrative
29users have followed this narrative
Vacaville And Visp Facilities Will Secure Future Biologics Demand
Lonza is betting big on new manufacturing sites like Vacaville and Visp to meet rising demand for complex biologic medicines, as drugmakers outsource more specialized production. The upside is steadier, higher-quality growth, but delays, uneven use of these plants, and tougher competition could quickly change the story.Read more
AN
CHF 677.61
19.1% undervalued intrinsic discount
Fair Value
Revenue
11.22% p.a.
Profit Margin
19.93%
Future PE
28.2x
Price in 2029
CHF 771.01
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
LONN: Bioprocessing Recovery And ADC Deals Will Support Future Upside
Fair Value: CHF 677.61 19.1% undervalued intrinsic discount
29 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Lonza Group AG Key Details
Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
- 15.48
- 37.14%
- 15.73%
- 51.1%
About LONN
- Founded
- 1897
- Employees
- 20141
- CEO
- WebsiteView website
Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Integrated Biologics; Advanced Synthesis; and Specialized Modalities segments. The Integrated Biologics segment offers CDMO biologics services from clinical development, drug substance, and drug product manufacturing; and operates mammalian and drug product platforms. Its Advanced Synthesis segment manufactures antibody-drug conjugates (ADCs) and other bioconjugates, small molecules, and highly potent active pharmaceutical ingredients; and operates small molecules and bioconjugates platforms. The Specialized Modalities segment operates various technologies, such as spanning cell & gene, microbial, bioscience, and mRNA. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.
